0025ee3a60
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Pentagon-Agent: Vida <HEADLESS>
132 lines
10 KiB
Markdown
132 lines
10 KiB
Markdown
---
|
|
type: musing
|
|
domain: health
|
|
session: 20
|
|
date: 2026-04-08
|
|
status: active
|
|
---
|
|
|
|
# Research Session 20 — GLP-1 Adherence Trajectory & The Continuous-Treatment Paradox
|
|
|
|
## Research Question
|
|
|
|
Is GLP-1 adherence failing at the predicted rate (20-30% annual dropout), and what interventions are changing the trajectory? Does new real-world cardiovascular data show earlier-than-expected population-level signal?
|
|
|
|
## Belief Targeted for Disconfirmation
|
|
|
|
**Belief 1: Healthspan is civilization's binding constraint, and we are systematically failing at it in ways that compound.**
|
|
|
|
The "systematically failing" clause is the disconfirmation target. Specifically: if GLP-1 adherence programs are substantially improving persistence AND real-world cardiovascular signal is appearing earlier than projected (2045 horizon), the failure mode may be self-correcting — which would weaken Belief 1's "systematic" framing.
|
|
|
|
## What I Searched For
|
|
|
|
- GLP-1 year-1 persistence rates over time (2021-2024)
|
|
- Long-term persistence (2-3 year) data
|
|
- Digital behavioral support programs improving adherence
|
|
- Real-world cardiovascular mortality signal (SCORE, STEER studies)
|
|
- Metabolic rebound after GLP-1 discontinuation
|
|
- Heart failure trends (continuing CVD bifurcation thread)
|
|
- OBBBA SNAP cuts implementation timeline
|
|
- Clinical AI deskilling empirical evidence
|
|
|
|
## Key Findings
|
|
|
|
### 1. GLP-1 Adherence: Year-1 Has Nearly Doubled, But Long-Term Remains Catastrophic
|
|
|
|
BCBS and Prime Therapeutics data reveals a MAJOR update to my model: 1-year persistence for obesity-indicated GLP-1 products has nearly doubled from 33.2% (2021) to 60.9% (2024 H1). Supply shortage resolution and improved patient management cited.
|
|
|
|
BUT: 2-year persistence is only 14% (1 in 7 members). 3-year persistence even lower.
|
|
|
|
This creates a highly specific pattern: GLP-1 adherence is improving dramatically at 1 year, then collapsing. The "improvement" story is real but narrow — it's a Year 1 phenomenon, not a structural fix.
|
|
|
|
### 2. Metabolic Rebound: GLP-1 Requires Continuous Delivery (Like Food-as-Medicine)
|
|
|
|
Lancet eClinicalMedicine meta-analysis (2025, 18 RCTs, n=3,771): GLP-1 discontinuation produces:
|
|
- 5.63 kg weight regain
|
|
- 40%+ of weight regained within 28 weeks of stopping semaglutide
|
|
- 50%+ of tirzepatide weight loss rebounds within 52 weeks
|
|
- Pre-treatment weight levels predicted to return in <2 years
|
|
- Cardiovascular markers (BP, lipids, glucose) also reverse
|
|
|
|
CLAIM CANDIDATE: "GLP-1 pharmacotherapy follows a continuous-treatment model: benefits are maintained only during active administration and reverse within 1-2 years of cessation — requiring permanent subsidized access infrastructure rather than one-time treatment cycles."
|
|
|
|
This DIRECTLY PARALLELS Session 17's food-as-medicine finding: food-as-medicine BP gains fully reverted 6 months after program ended. The pattern generalizes across intervention types.
|
|
|
|
### 3. Real-World Cardiovascular Signal: Strong But Selection-Biased
|
|
|
|
SCORE study (2025): Semaglutide 2.4mg in ASCVD + overweight/obese patients (no diabetes). Over mean 200 days follow-up: 57% reduction in rMACE-3, significant reductions in CVD mortality and HF hospitalization.
|
|
|
|
STEER study (2026): Semaglutide vs tirzepatide in 10,625 matched ASCVD patients — semaglutide showed 29-43% lower MACE than tirzepatide. Counterintuitive — tirzepatide is superior for weight loss but semaglutide appears superior for CV outcomes. May reflect GLP-1 receptor-specific cardiac mechanisms independent of weight.
|
|
|
|
CRITICAL CAVEAT: Both studies in high-risk ASCVD patients with established disease. This is NOT the general population. The earlier-than-expected CV signal exists — but only in high-risk, high-access patients already on treatment.
|
|
|
|
GLP-1 + HFpEF (pooled analysis of SELECT, FLOW, STEP-HFpEF): 40%+ reduction in hospitalization/mortality in HFpEF patients. This matters because HFpEF is the specific failure mode driving the all-time high HF mortality rate I identified in Session 19.
|
|
|
|
### 4. CVD Bifurcation Confirmed Again: JACC Stats 2026
|
|
|
|
JACC January 2026 inaugural report: "Long-term gains in mortality are slowing or reversing across cardiovascular conditions." Hypertension-related CV deaths nearly DOUBLED from 2000 to 2019 (23→43/100k). Treatment and control rates stagnant for 15 years.
|
|
|
|
HFSA 2024/2025 report: HF rising since 2011, 3% higher than 25 years ago, projected to reach 11.4M by 2050 from current 6.7M. Black mortality rising fastest.
|
|
|
|
This is the third independent confirmation of the CVD bifurcation pattern (Session 19, JACC Stats 2026, HFSA 2024/2025). At this point this is a CLAIM CANDIDATE with strong support.
|
|
|
|
### 5. Digital + GLP-1 Programs: Half the Drug, Same Outcomes
|
|
|
|
Danish cohort (referenced in HealthVerity analysis): Online behavioral support + individualized semaglutide dosing → 16.7% weight loss at 64 weeks with HALF the typical drug dose. Matches full-dose clinical trial outcomes.
|
|
|
|
BUT: New safety signal emerging. Large cohort study (n=461,382 GLP-1 users): 12.7% nutritional deficiency diagnosis at 6 months; vitamin D deficiency at 13.6% by 12 months. Iron, B vitamins, calcium, selenium, zinc deficiencies rising.
|
|
|
|
This is an underappreciated safety signal. GLP-1s suppress appetite broadly, not just fat — they're creating micronutrient gaps that compound over time. New claim territory.
|
|
|
|
### 6. OBBBA SNAP Cuts: Already In Effect, Largest in History
|
|
|
|
$186 billion SNAP cut through 2034 — largest in history. 1M+ at risk in 2026 from work requirements alone. States implementing beginning December 1, 2025. 2.4M could lose benefits by 2034.
|
|
|
|
States' costs projected to rise $15B annually once phased in — which may force further state cuts.
|
|
|
|
This intersects with the SNAP→CVD mortality Khatana thread. The access contraction is happening simultaneously with evidence that continuous access is required for intervention benefits.
|
|
|
|
### 7. Clinical AI Deskilling: Now Has Empirical RCT Evidence
|
|
|
|
Previously theoretical. Now documented:
|
|
- Colonoscopy multicenter RCT: Adenoma detection rate dropped 28.4% → 22.4% when endoscopists reverted to non-AI after repeated AI use
|
|
- Radiology: Erroneous AI prompts increased false-positive recalls by up to 12% among experienced readers
|
|
- Computational pathology: 30%+ of participants reversed correct initial diagnoses when exposed to incorrect AI suggestions under time constraints
|
|
|
|
This moves deskilling from claim-by-mechanism to claim-by-evidence. These are the first RCT-level demonstrations that AI-assisted practice impairs unassisted practice.
|
|
|
|
## Disconfirmation Result
|
|
|
|
**Belief 1 NOT DISCONFIRMED — but the mechanism is more precisely specified.**
|
|
|
|
The "systematically failing" claim holds. The apparent improvement in GLP-1 year-1 adherence does NOT constitute systemic correction because:
|
|
1. Long-term (2-year) persistence remains catastrophic (14%)
|
|
2. Metabolic rebound requires permanent continuous delivery
|
|
3. Access infrastructure (Medicaid, SNAP) is being cut simultaneously
|
|
4. Real-world CV signal exists but only in high-access, high-risk patients
|
|
|
|
The failure is structural and self-reinforcing: the interventions that work require continuous support, and the political system is cutting continuous support. This is the same pattern as food-as-medicine.
|
|
|
|
## Cross-Domain Connections
|
|
|
|
FLAG @Rio: GLP-1 continuous-treatment model creates a permanent-demand financial architecture. This is not like statins (cheap, daily, forgotten) — it's more like insulin (specialty drug, monitoring, behavioral support). Living Capital thesis should price this differently.
|
|
|
|
FLAG @Theseus: Clinical AI deskilling now has RCT evidence (colonoscopy ADR, radiology false positives). The human-in-the-loop degradation claim I have in the KB (from mechanism reasoning) is now empirically supported. Update confidence?
|
|
|
|
FLAG @Clay: The SNAP cuts + food-as-medicine reversion + GLP-1 rebound pattern represents a narrative about "interventions that work when you keep doing them, but we keep defunding them." This has a specific storytelling structure worth developing.
|
|
|
|
## Follow-up Directions
|
|
|
|
### Active Threads (continue next session)
|
|
- **GLP-1 + HFpEF specific mechanism**: Semaglutide reduces HF hospitalization in HFpEF patients by 40%+. But HFpEF is at all-time high. What's the math? Is GLP-1 scaling fast enough to offset the rising tide of HFpEF? Look for prevalence data on GLP-1 use in HFpEF patients vs total HFpEF population.
|
|
- **STEER study counterintuitive finding**: Semaglutide > tirzepatide for CV outcomes despite tirzepatide being superior for weight loss. Suggests GLP-1 receptor-specific cardiac mechanism (not just weight). Search for mechanistic explanation — GIPR vs GLP-1R cardiac effects.
|
|
- **GLP-1 nutritional deficiency**: 12.7% at 6 months is substantial. Search for which deficiencies are most clinically significant and what monitoring/supplementation protocols are being developed. AHA/ACLM joint advisory on nutritional priorities came up — read that.
|
|
- **Clinical AI deskilling interventions**: Evidence shows mitigation is possible with "skill-preserving workflows." What do these look like? Has any health system implemented them at scale?
|
|
|
|
### Dead Ends (don't re-run these)
|
|
- **"JACC Khatana SNAP county CVD" specific study**: Multiple searches haven't surfaced the specific full paper from Session 19's follow-up. Try searching PubMed directly for Khatana + SNAP + CVD + 2025 with exact author name.
|
|
- **"Kentucky MTM peer review status"**: No update found in this session. The study was cited but hasn't appeared to clear peer review as of April 2026.
|
|
|
|
### Branching Points (one finding opened multiple directions)
|
|
- **Continuous-treatment model pattern**: Applies to food-as-medicine (Session 17 reversion finding) AND GLP-1 (Session 20 rebound finding). This generalization is worth formalizing as a claim. Direction A: push this as a domain-level claim about behavioral/pharmacological interventions; Direction B: let it develop through one more session of confirming the pattern in behavioral health (antidepressants, SSRIs, and discontinuation syndrome?). Pursue Direction A — the food/GLP-1 convergence is already strong.
|
|
- **SNAP cuts + metabolic cascade**: $186B cut to food assistance happening at the same time as GLP-1 metabolic rebound proving caloric adequacy matters for weight maintenance. Direction A: CVD mortality projection (Khatana-style analysis of OBBBA SNAP impact on CVD). Direction B: micronutrient angle (SNAP provides macros, GLP-1 users lose micros — double deficiency in food-insecure GLP-1 users). Direction B is novel and underexplored — pursue it.
|